Empirical, Pre-emptive and Prophylactic Therapy of Invasive Mycoses: Current State of the Problem

Clinical Microbiology and Antimicrobial Chemotherapy. 2009; 11(4):286-304

​ Veselov A.V.
invasive mycoses neutropenia ICU transplantation prophylaxis empirical therapy pre-emptive therapy
Section
Diseases and Pathogens
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2009; 11(4):286-304

Abstract

Invasive mycoses in patients with severe diseases – ICU patients, patients with hematological malignancies and after solid organ transplantations represent a significant target for the use of prophylactic, empirical and pre-emptive antifungal therapy. This is not only because of high incidence of invasive mycoses among this population but also because of high mortality levels and diseaserelated costs. There is no doubt that as early as possible diagnosis provides the most favorable prognosis in this group of patients. Currently there is substantial number of antifungal drugs for systemic use that allows us to make an adequate choice of therapy in particular patient according to clinical scenario, the presence of certain risk factors, epidemiological data regarding potential etiological agents and overall clinical pharmacology of antifungal agents. In the current article the information regarding prophylactic, pre-emptive and empirical therapy of invasive mycoses in different categories of patients will be presented. Also some aspects of diagnostic approaches on invasive fungal infections will be discussed.

  • 1. Cordonnier C., Ribaud P., Herbrecht R., et al. Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers. Clin Infect Dis 2006; 42:955-63.
  • 2. Barnes R.A., White P.L., Bygrave C., et al. Clinical impact of enhanced diagnosis of invasive fungal disease in high-risk haematology and stem cell transplant patients. J Clin Pathol 2009; 62:64-9.
  • 3. Ascioglu S., Rex J.H., de Pauw B., et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34:7-14.
  • 4. Maertens J., Verhaegen J., Lagrou K., et al. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001; 97:1604-10.
  • 5. Meersseman W., Lagrou K., Maertens J., et al. Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med 2008; 177:27-34.
  • 6. Odabasi Z., Mattiuzzi G., Estey E., et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004; 39:199-205.
  • 7. Pickering J.W., Sant H.W., Bowles C.A., et al. Evaluation of a (1-3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 2005; 43:5957-62.
  • 8. Ostrosky-Zeichner L., Alexander B.D., Kett D.H., et al. Multicenter clinical evaluation of the (1-3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005; 41:654-9.
  • 9. Maertens J., Deeren D., Dierickx D., Theunissen K. Preemptive antifungal therapy: still a way to go. Curr Opin Infect Dis 2006; 19:551-6.
  • 10. Quindуs G., Moragues M.D., Pontуn J. Is there a role for antibody testing in the diagnosis of invasive candidiasis? Rev Iberoam Micol 2004; 21:10-4.
  • 11. Moragues M.D., Ortiz N., Iruretagoyena J.R., et al. Evaluation of a new commercial test (Candida albicans IFA IgG) for the serodiagnosis of invasive candidiasis. Enferm Infecc Microbiol Clin 2004; 22:83-8.
  • 12. Hui M., Cheung S.W., Chin M.L., et al. Development and application of a rapid diagnostic method for invasive candidiasis by the detection of D-/L-arabinitol using gas chromatography/mass spectrometry. Diagn Microbiol Infect Dis 2004; 49:117-23.
  • 13. Laнn A., Moragues M.D., Ruiz J.C., et al. Evaluation of a novel enzyme-linked immunosorbent assay to detect immunoglobulin G antibody to enolase for serodiagnosis of invasive candidiasis. Clin Vaccine Immunol 2007; 14:318-9.
  • 14. Pazos C., Pontуn J., Del Palacio A. Contribution of (1- 3)-beta-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol 2005; 43:299-305.
  • 15. Florent M., Katsahian S., Vekhoff A., et al. Prospective evaluation of a polymerase chain reaction-ELISA targeted to Aspergillus fumigatus and Aspergillus flavus for the early diagnosis of invasive aspergillosis in patients with hematological malignancies. J Infect Dis 2006; 193:741- 7.
  • 16. Pazos C., Moragues M.D., Quindуs G., et al. Diagnostic potential of (1,3)-beta-D-glucan and anti-Candida albicans germ tube antibodies for the diagnosis and therapeutic monitoring of invasive candidiasis in neutropenic adult patients. Rev Iberoam Micol 2006; 23:209-15.
  • 17. Hiemenz J.W. Management of infections complicating allogeneic hematopoietic stem cell transplantation. Semin Hematol 2009; 46:289-312.
  • 18. Herbrecht R. Posaconazole: a potent, extended-spectrum triazole antifungal for the treatment of serious fungal infections. Int J Clin Pract 2004; 58:612-24.
  • 19. National Comprehensive Cancer Network. NCCN Practice Guidelines in Oncology: prevention and treatment of cancer-related infections. V.1.2008. Available at: http://www.nccn.org/professionals/physician_gls/PDF/infections.pdf.
  • 20. Walsh T.J., Anaissie E.J., Denning D.W., et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:327-60.
  • 21. Cornely O.A., Maertens J., Winston D.J., et al. Posaconazole vs fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356:348-59.
  • 22. Ullmann A.J., Lipton J.H., Vesole D.H., et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356:335-47.
  • 23. O’Sullivan A., Pandya A., Papadopoulos G., et al. Costeffectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States. Value Health 2009 Jan 9. [Epub ahead of print].
  • 24. Marr K.A., Crippa F., Leisenring W., et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004; 103:1527-33.
  • 25. van Burik J.A., Ratanatharathorn V., Stepan D.E., et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004; 39:1407-16.
  • 26. Chou L.S., Lewis R.E., Ippoliti C., et al. Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients. Pharmacother 2007; 27:1644-50.
  • 27. de Fabritiis P., Spagnoli A., Di Bartolomeo P., et al. Efficacy of caspofungin as secondary prophylaxis in patients undergoing allogeneic stem cell transplantation with prior pulmonary and/or systemic fungal infection. Bone Marrow Transplant 2007; 40:245-9.
  • 28. Rijnders B.J., Cornelissen J.J., Slobbe L., et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 2008; 46:1401-8.
  • 29. De Pauw B.E. Between over- and undertreatment of invasive fungal disease. Clin Infect Dis 2005; 41:1251-3.
  • 30. Bow E.J, Laverdiere M., Lussier N., et al. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta-analysis of randomized-controlled clinical trials. Cancer 2002; 94:3230-46.
  • 31. Ullmann A.J., Heussel C.P., Cornely O.A. Voriconazole versus liposomal amphotericin B for empirical antifungal therapy. N Engl J Med 2002; 346:1745-7.
  • 32. Hughes W.T., Armstrong D., Bodey G.P., et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34:730- 51.
  • 33. Walsh T.J., Teppler H., Donowitz G.R., et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351:1391-402.
  • 34. Walsh T.J., Pappas P., Winston D.J., et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346:225-34.
  • 35. Jшrgensen K.J., Gшtzsche P.C., Johansen H.K. Voriconazole versus amphotericin B in cancer patients with neutropenia. Cochrane Database Syst Rev 2006; (1):CD004707.
  • 36. Eriksson U., Seifert B., Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomized controlled trial. BMJ 2001; 322:579-82.
  • 37. Peleg A.Y., Woods M.L. Continuous and 4 h infusion of amphotericin B: a comparative study involving high-risk haematology patients. J Antimicrob Chemother 2004; 54:803-8.
  • 38. Maertens J., Theunissen K., Verhoef G., et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005; 41:1242-50.
  • 39. Hebart H., Klingspor L., Klingebeihl T., et al. A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT. Bone Marrow Transplant 2009; 43:553-61.
  • 40. Cordonnier C., Pautas C., Maury S., et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 2009; 48:1042-51.
  • 41. Greene R.E., Schlamm H.T., Oestmann J.W., et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007; 44:373-9.
  • 42. Alberti C., Brun-Buisson C., Burchardi H., et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med 2002; 28:108-21.
  • 43. Dimopoulos G., Piagnerelli M., Berrй J., Salmon I., Vincent J.L. Post mortem examination in the intensive care unit: still useful? Intensive Care Med 2004; 30:2080- 5.
  • 44. Tortorano A.M., Caspani L., Rigoni A.L., et al. Candidosis in the intensive care unit: a 20-year survey. J Hosp Infect 2004; 57:8-13.
  • 45. Leleu G., Aegerter P., Guidet B., et al. Systemic candidiasis in intensive care units: a multicenter, matched-cohort study. J Crit Care 2002; 17:168-75.
  • 46. Almirante B., Rodrнguez D., Park B.J., et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005; 43:1829-35.
  • 47. Pfaller M.A., Diekema D.J., Gibbs D.L., et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2009; 47:117-23.
  • 48. Morgan J. Global trends in candidemia: review of reports from 1995-2005. Curr Infect Dis Rep 2005; 7:429-39.
  • 49. Dimopoulos G., Ntziora F., Rachiotis G., et al. Candida albicans versus non-albicans intensive care unit-acquired bloodstream infections: differences in risk factors and outcome. Anesth Analg 2008; 106:523-9.
  • 50. Ben-Abraham R., Keller N., Teodorovitch N., et al. Predictors of adverse outcome from candidal infection in a tertiary care hospital. J Infect 2004; 49:317-23.
  • 51. Nolla-Salas J., Sitges-Serra A., Leуn-Gil C., et al. Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU. Intensive Care Med 1997; 23:23-30.
  • 52. Parkins M.D., Sabuda D.M., Elsayed S., Laupland K.B. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J Antimicrob Chemother 2007; 60:613-8.
  • 53. Morrell M., Fraser V.J., Kollef M.H., et al. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49:3640-5.
  • 54. Garey K.W., Rege M., Pai M.P., et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43:25-31.
  • 55. Calandra T., Marchetti O. Antifungal prophylaxis for intensive care unit patients: let’s fine tune it. Intensive Care Med 2002; 28:1698-700.
  • 56. Eggimann P., Francioli P., Bille J., et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in highrisk surgical patients. Crit Care Med 1999; 27:1066-72.
  • 57. Pelz R.K., Hendrix C.W., Swoboda S.M., et al. Doubleblind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg 2001; 233:542-8.
  • 58. Garbino J., Lew D.P., Romand J.A., et al. Prevention of severe Candida infections in nonneutropenic, highrisk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med 2002; 28:1708-17.
  • 59. Cruciani M., de Lalla F., Mengoli C. Prophylaxis of Candida infections in adult trauma and surgical intensive care patients: a systematic review and meta-analysis. Intensive Care Med 2005; 31:1479-87.
  • 60. Shorr A.F., Chung K., Jackson W.L., et al. Fluconazole prophylaxis in critically ill surgical patients: a metaanalysis. Crit Care Med 2005; 33:1928-35.
  • 61. Playford E.G., Webster A.C., Sorrell T.C., et al. Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials. J Antimicrob Chemother 2006; 57:628-38.
  • 62. Lam S.W., Eschenauer G.A., Carver P.L. Evolving role of early antifungals in the adult intensive care unit. Crit Care Med 2009; 37:1580-93.
  • 63. Piarroux R., Grenouillet F., Balvay P., et al. Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients. Crit Care Med 2004; 32:2443-9.
  • 64. De Waele J.J., Vogelaers D., Blot S., et al. Fungal infections in patients with severe acute pancreatitis and the use of prophylactic therapy. Clin Infect Dis 2003; 37:208-13.
  • 65. Blumberg H.M., Jarvis W.R., Soucie J.M., et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 2001; 33:177-86.
  • 66. Alvarez-Lerma F., Palomar M., Leon C., et al. 2003. Colonizaciуn y/o infecciуn fъngica en unidades de cuidados intensivos. Estudio multicйntrico de 1.562 pacientes. Med Clin (Barc) 2003; 121:161-6.
  • 67. Ibanez-Nolla J., Nolla-Salas M., Leon M.A., et al. Early diagnosis of candidiasis in non-neutropenic critically ill patients. J Infect 2004; 48:181-92.
  • 68. Garnacho-Montero J., Leуn C., Almirante B., et al. Recomendaciones terapйuticas para infecciones fъngicas en el paciente crнtico no neutropйnico. Conferencia de consenso. Conclusiones. Med Intensiva 2005; 3(Suppl 1):43-52.
  • 69. Ostrosky-Zeichner L., Sable C., Sobel J., et al. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 2007; 26:271-6.
  • 70. Leon C., Ruiz-Santana S., Saavedra P., et al. A bedside scoring system (“Candida score”) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 2006; 34:730-7.
  • 71. Marik P.E. Fungal infections in solid organ transplantation. Expert Opin Pharmacother 2006; 7:297-305.
  • 72. Solй A., Salavert M. Voriconazole for the therapy of mycoses in recipients of solid organ transplants. Rev Iberoam Micol 2007; 24:217-22.
  • 73. Pappas P.G., Andes D., Schuster M., et al. Invasive fungal infections in low-risk liver transplant recipients: a multicenter prospective observational study. Am J Transplant 2006; 6:386-91.
  • 74. Husain S., Zaldonis D., Kusne S., et al. Variation in antifungal prophylaxis strategies in lung transplantation. Transpl Infect Dis 2006; 8:213-8.
  • 75. Magill S.S., Dropulic L.K. Antifungal prophylaxis in transplant recipients: where do we go from here? Transpl Infect Dis 2006; 8:187-9.
  • 76. Drew R. Potential role of aerosolized amphotericin B formulations in the prevention and adjunctive treatment of invasive fungal infections. Int J Antimicrob Agents 2006; 27:36-44.
  • 77. Monforte V., Roman A., Gavaldб J., et al. Nebulized amphotericin B concentration and distribution in the respiratory tract of lung-transplanted patients. Transplantation 2003; 75:1571-4.
  • 78. Calvo V., Borro J.M., Morales P., et al. Antifungal prophylaxis during the early postoperative period of lung transplantation. Valencia Lung Transplant Group. Chest 1999; 115:1301-4.
  • 79. Monforte V., Roman A., Gavalda J., et al. Nebulized amphotericin B prophylaxis for Aspergillus infection in lung transplantation: study of risk factors. J Heart Lung Transplant 2001; 20:1274-81.
  • 80. Lowry C.M., Marty F.M., Vargas S.O., et al. Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study. Transpl Infect Dis 2007; 9:121-5.
  • 81. Monforte V., Ussetti P., Lуpez R., et al. Nebulized liposomal amphotericin B prophylaxis for Aspergillus infection in lung transplantation: pharmacokinetics and safety. J Heart Lung Transplant 2009; 28:170-5.
  • 82. Sanmartнn E, Morales P, Monte E, Vicente R. A comparison of several formats of amphotericin B as an inhaled antifungal prophylaxis. Transplant Proc 2009; 41:2225- 6.
  • 83. Husain S., Paterson D.L., Studer S., et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant 2006; 6:3008-16.
  • 84. Wong-Beringer A., Lambros M.P., Beringer P.M., Johnson D.L. Suitability of caspofungin for aerosol delivery: physicochemical profiling and nebulizer choice. Chest 2005; 128:3711-6.
  • 85. Solй A., Morant P., Salavert M., et al. Aspergillus infections in lung transplant recipients: risk factors and outcome. Clin Microbiol Infect 2005; 11:359-65.
  • 86. Singh N., Husain S. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J Heart Lung Transplant 2003; 22:258-66.
  • 87. Eschenauer G.A., Lam S.W., Carver P.L. Antifungal prophylaxis in liver transplant recipients. Liver Transpl 2009; 15:842-58.
  • 88. Wiesner R.H., Hermans P.E., Rakela J., et al. Selective bowel decontamination to decrease gram-negative aerobic bacterial and Candida colonization and prevent infection after orthotopic liver transplantation. Transplantation 1988; 45:570-4.
  • 89. Arnow P.M., Carandang G.C., Zabner R., et al. Randomized controlled trial of selective bowel decontamination for prevention of infections following liver transplantation. Clin Infect Dis 1996; 22:997-1003.
  • 90. Hjortrup A., Rasmussen A., Hansen B.A., et al. Early bacterial and fungal infections in liver transplantation after oral selective bowel decontamination. Transplant Proc 1997; 29:3106-10.
  • 91. Lumbreras C., Cuervas-Mons V., Jara P., et al. Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation. J Infect Dis 1996; 174:583-8.
  • 92. Sharpe M.D., Ghent C., Grant D., et al. Efficacy and safety of Itraconazole prophylaxis for fungal infections after orthotopic liver transplantation: a prospective, randomized, double-blind study. Transplantation 2003; 76:977-83.
  • 93. Cruciani M., Mengoli C., Malena M., et al. Antifungal prophylaxis in liver transplant patients: a systematic review and meta-analysis. Liver Transpl 2006; 12:850-8.
  • 94. Singh N., Paterson D.L., Gayowski T., et al. Preemptive prophylaxis with a lipid preparation of amphotericin B for invasive fungal infections in liver transplant recipients requiring renal replacement therapy. Transplantation 2001; 71:910-3.
  • 95. Fortun J., Martin-Davila P., Moreno S., et al. Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patients. J Antimicrob Chemother 2003; 52:813-9.
  • 96. Winston D.J., Busuttil R.W. Randomized controlled trial of oral itraconazole solution versus intravenous/oral fluconazole for prevention of fungal infections in liver transplant recipients. Transplantation 2002; 74:688-95.
  • 97. Fortun J., Martin-Dowila P., Montejo M., et al.Prophylaxis with caspofungin for invasive fungal infections in high-risk liver transplant recipients. Transplantation 2009; 87:424-35.
  • 98. Munoz P., Rodriguez C., Bouza E., et al. Risk factors of invasive aspergillosis after heart transplantation: protective role of oral Itraconazole prophylaxis. Am J Transplant 2004; 4:636-43.
  • 99. Leather H.L., Wingard J.R. New strategies of antifungal therapy in hematopoietic stem cell transplant recipients and patients with hematological malignancies. Blood Rev 2006; 20:267-87.
  • 100. Salavert M. Prophylaxis, pre-emptive or empirical antifungal therapy: which is best in non-lung transplant recipients? Int J Antimicrob Agents 2008; 32(Suppl 2): S149-53.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared